CAS Number81403-68-1
SynonymsSL 77 499-10; Uroxatral; MFCD00879135; Alfuzosin HCl; SL 77-499-10; Alfuzosin hydrochloride; Alfuzosin (hydrochloride)
Molecular FormulaC19H28ClN5O4
Molecular Weight425.91
Purity98%
Density1.272 g/cm3
Boiling Point687.7ºC at 760 mmHg
Melting Point225°C
AppearanceWhite to off-white solid
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 81403-68-1 |
| Catalog No. | 2A-9009102 |
| Chinese Name | 盐酸阿夫唑嗪 |
| Synonyms | SL 77 499-10; Uroxatral; MFCD00879135; Alfuzosin HCl; SL 77-499-10; Alfuzosin hydrochloride; Alfuzosin (hydrochloride) |
| Molecular Formula | C19H28ClN5O4 |
| Molecular Weight | 425.91 |
| Purity | 98 |
| Density | 1.272 g/cm3 |
| Boiling Point | 687.7ºC at 760 mmHg |
| Melting Point | 225°C |
| Appearance | White to off-white solid |
| Storage Condition | Store at RT |
| Application | Alfuzosin hydrochloride is an α1-adrenergic receptor antagonist that acts on benign prostatic hyperplasia (BPH). |
| PubChem ID | 329823527 |
| MDL Number | MFCD00879135 |
| SMILES | Cl.COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3 |
| InChI | 1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H |
| InChI Key | YTNKWDJILNVLGX-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | Transport |
| MSDS | msds/9102_1_81403_68_1.pdf |
| Bioactivity | Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).Target: α1 adrenergic receptorAlfuzosin, a new quinazoline derivative, acts as a selective and competitive antagonist of alpha 1-adrenoceptor-mediated contraction of prostatic, prostatic capsule, bladder base and proximal urethral smooth muscle, thereby reducing the tone of these structures. Consequently, urethral pressure and resistance, bladder outlet resistance, bladder instability and symptoms associated with benign prostatic hyperplasia are reduced. A limited range of clinical studies have shown oral alfuzosin to be more effective than placebo (in studies of < or = 6 months duration), to have sustained effects on long term administration (< or = 30 months), and to be comparable with the alpha 1-adrenoceptor antagonist prazosin, in the symptomatic treatment of benign prostatic hyperplasia.Oral alfuzosin 7.5 to 10 mg/day in divided doses appears to be a promising first-line agent for symptomatic treatment of noncomplicated mild to moderate benign prostatic hyperplasia in patients with a high dynamic component to their obstruction. In addition, alfuzosin offers an alternative to prostatectomy (the current 'gold standard') in patients who require surgery but are unfit for this treatment, and in patients requiring symptomatic relief while awaiting surgery. Related Catalog Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Natural Products >> Alkaloid Research Areas >> Endocrinology References [1]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. Chemical & Physical Properties Density 1.272 g/cm3 Boiling Point 687.7ºC at 760 mmHg Melting Point 225°C Molecular Formula C19H28ClN5O4 Molecular Weight 425.910 Exact Mass 425.182983 PSA 111.83000 LogP 3.12480 InChIKey YTNKWDJILNVLGX-UHFFFAOYSA-N SMILES COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl Storage condition Store at RT |
| Use of | Properties Name alfuzosin hydrochloride Synonym More Synonyms Alfuzosin hydrochloride Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Natural Products >> Alkaloid Research Areas >> Endocrinology References [1]. Wilde MI, et al. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. Chemical & Physical Properties Exact Mass 425.182983 PSA 111.83000 LogP 3.12480 InChIKey YTNKWDJILNVLGX-UHFFFAOYSA-N Storage condition Store at RT |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Albendazole | 54965-21-8 | 2A-9009089 |
| Albuterol | 18559-94-9 | 2A-9009091 |
| Alendronate sodium USP | 2A-300179 | 2A-9009096 |
| Alfentanil hydrochloride | 69049-06-5 | 2A-9009100 |
| Alfuzosin | 81403-80-7 | 2A-9009101 |
| Allopurinol | 315-30-0 | 2A-9009113 |
| Allopurinol riboside | 16220-07-8 | 2A-9009114 |
| Amikacin disulfate salt | 39831-55-5 | 2A-9009154 |
| Aminophylline | 317-34-0 | 2A-9009158 |
| Amiodarone | 1951-25-3 | 2A-9009160 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS